Mast-Cell Skin Peptides in Canada: A Research Guide to Degranulation, Histamine, Neurogenic Inflammation, LL-37, KPV, and GHK-Cu

Why mast-cell skin biology needed its own peptide guide#

Northern Compound already covers cutaneous immune-surveillance peptides, vascular redness, pruritus and neurogenic inflammation, skin barrier peptides, skin microbiome models, and the focused LL-37 vs KPV comparison. Those articles mention mast cells where they matter. What was still missing was a mast-cell-first guide: how should Canadian readers evaluate peptide claims when the actual experimental layer is degranulation, histamine release, tryptase, neurogenic flare, itch-like signalling, or mast-cell participation in barrier stress?

That gap matters because mast cells are easy to flatten into bad marketing. A supplier page may cite reduced inflammation and imply calmer skin. A paper may report less histamine release and be repeated as if it proves anti-itch activity. A redness model may show less vascular flare and be turned into a cosmetic claim. A wound model may show altered immune timing and be described as repair support. Those are different claims.

Mast cells sit at the skin's interface with nerves, vessels, microbes, allergens, irritants, and injured tissue. They can release histamine, tryptase, chymase, cytokines, chemokines, prostaglandins, leukotrienes, growth factors, and antimicrobial mediators. They can respond through IgE-dependent pathways, complement, neuropeptides, microbial products, mechanical stress, temperature, and epithelial alarmins. A peptide that changes one mast-cell marker does not prove global skin benefit.

This guide is written for Canadian readers evaluating non-clinical, research-use-only peptide materials, endpoint logic, supplier documentation, and cautious evidence claims. It does not provide medical advice, allergy guidance, dermatology guidance, topical-use instructions, compounding instructions, dosing, route selection, or recommendations for personal use. Allergy, itch, rosacea, dermatitis, wound, and infection terms appear only because they are common in published model systems and supplier claims that require careful interpretation.

The short answer: define the mast-cell event before naming a peptide#

A defensible mast-cell skin project starts by naming the event under test. "Calms mast cells" is not an endpoint. Is the protocol measuring acute degranulation, histamine release, tryptase activity, cytokine production, neuropeptide-triggered flare, IgE-dependent activation, microbial challenge, keratinocyte-mast-cell crosstalk, barrier leakage, wound-edge repair timing, or vascular permeability? Each answer changes the peptide shortlist and the claim boundary.

Within the current Northern Compound product map, LL-37 is the strongest live reference when the hypothesis involves cathelicidin biology, microbial challenge, keratinocyte danger signalling, innate immune amplification, or rosacea-like mast-cell context. KPV is the better fit when the question is cytokine restraint, melanocortin-adjacent inflammatory tone, or epithelial immune signalling. GHK-Cu belongs when mast-cell state is being interpreted alongside fibroblast matrix remodelling, copper-peptide biology, wound-edge signalling, or repair-associated inflammation. Melanotan-1 is relevant only when UV or melanocortin biology is an upstream stressor. Thymosin Alpha-1 can be a broader immune comparator when antigen-presentation or T-cell-adjacent context is explicitly part of the study.

Those links are documentation checkpoints for research-use-only materials. They are not evidence that any material treats allergy, itch, redness, dermatitis, infection, mast-cell activation, or any personal skin condition.

Mast-cell skin biology in one cautious map#

Mast cells are tissue-resident immune cells positioned near vessels, nerves, glands, follicles, and barrier surfaces. In skin, they can respond quickly to environmental and tissue signals. Their granules contain preformed mediators such as histamine and proteases, while activated cells can also generate lipid mediators and produce cytokines over time. That timing matters: an early degranulation assay and a later cytokine assay may describe different biological layers.

Skin immune reviews describe the barrier as an integrated organ where keratinocytes, antimicrobial peptides, dendritic cells, macrophages, mast cells, nerves, vessels, fibroblasts, and microbiome signals interact rather than acting as isolated compartments (PMID: 24305619; PMC6351085). Mast cells are one node in that network. They can amplify danger signals, alter vascular permeability, recruit immune cells, participate in host defence, and communicate with sensory nerves.

The practical implication for peptide research is that a mast-cell endpoint is rarely self-explanatory. More histamine may indicate activation, irritation, allergy-like stimulation, cytotoxicity, or a deliberate host-defence response. Less histamine may indicate restraint, receptor blockade, cell injury, assay interference, depletion, or delayed release. Tryptase can support a mast-cell activation readout, but it does not automatically identify the trigger. A cytokine panel can show inflammatory tone, but it does not prove degranulation.

Mast cells also bridge several Northern Compound skin topics. In vascular redness, mast cells can participate in flare, vessel permeability, neurogenic inflammation, and rosacea-like innate immunity. In pruritus research, mast cells can release histamine and proteases, but itch may also be non-histaminergic through IL-31, TSLP, TRP channels, and sensory-neuron sensitisation. In cutaneous immune surveillance, mast cells are part of the broader skin defence network. This article isolates the mast-cell layer so those adjacent claims do not blur together.

LL-37: cathelicidin context can activate, protect, or confound mast-cell models#

LL-37 is the most coherent peptide reference for mast-cell-adjacent skin research when the model involves cathelicidin biology, microbial challenge, keratinocyte danger signalling, or innate immune amplification. LL-37 is the active peptide form of human cathelicidin and appears across antimicrobial, epithelial, immune, wound, and inflammatory skin contexts. Reviews emphasize its context dependence rather than a one-direction effect (PMID: 15351772; PMC3699762).

That context dependence is the whole point. LL-37 can interact with microbial membranes, host-cell membranes, nucleic acids, proteases, salts, serum proteins, and glycosaminoglycans. It may be antimicrobial in one condition, immunostimulatory in another, cytotoxic at a different exposure, and biologically muted when bound or degraded. A mast-cell model that includes LL-37 should therefore define whether the hypothesis is direct mast-cell activation, keratinocyte-driven mediator release, microbial challenge, rosacea-like cathelicidin processing, or wound-edge signalling.

A useful LL-37 mast-cell panel might include histamine, tryptase, beta-hexosaminidase, calcium flux, mast-cell viability, keratinocyte viability, IL-8, TNF-alpha, IL-1 beta, kallikrein or cathelicidin-fragment context where relevant, microbial burden if microbes are present, and barrier readouts if tissue is involved. It should also include concentration response and peptide recovery. If a study measures only one mediator, the conclusion should stay narrow.

Supplier documentation is unusually important for LL-37 because membrane-active and immune-active assays are sensitive to purity, oxidation, adsorption, endotoxin, residual solvent, salts, storage, and concentration error. Canadian readers should inspect lot-specific HPLC purity, mass confirmation, fill amount, batch number, storage guidance, and RUO labelling before treating a mast-cell signal as interpretable.

KPV: cytokine restraint is not the same as mast-cell stabilisation#

KPV is an alpha-MSH-derived tripeptide discussed in epithelial and immune research around inflammatory signalling. In mast-cell skin models, KPV is best framed as a cytokine-tone or melanocortin-adjacent research tool, not as a generic mast-cell stabiliser.

The distinction matters. A peptide can reduce NF-kB-linked cytokine output in one cell type without preventing degranulation. It can lower keratinocyte inflammatory markers without acting directly on mast cells. It can reduce a late cytokine while acute histamine release remains unchanged. It can also appear favourable because the exposure harmed the cells. A mast-cell article should not call KPV "anti-allergic" or "mast-cell stabilising" unless the model actually measures mast-cell activation and controls for viability.

A stronger KPV protocol would state whether the primary layer is mast cells, keratinocytes, co-culture, reconstructed skin, or an animal inflammation model. It would measure degranulation markers if the claim is degranulation. It would measure cytokines if the claim is inflammatory tone. It would add barrier markers if the claim involves skin integrity. It would add sensory-neuron or behaviour endpoints only if the claim involves itch or neurogenic inflammation. A single reduced cytokine is not enough.

For Canadian RUO sourcing, the same discipline applies: exact identity, lot-specific COA, purity method, batch number, fill, storage, and clear research-use-only positioning. A tracked product link lets readers inspect supplier documentation. It does not imply that KPV treats allergies, dermatitis, itch, redness, or mast-cell disorders.

GHK-Cu: repair context can change mast-cell state, but matrix is not degranulation#

GHK-Cu belongs in mast-cell skin content only when the study connects mast-cell state to matrix repair, wound-edge biology, fibroblast signalling, oxidative stress, or dermal remodelling. It is not the first peptide to choose for an acute histamine-release assay unless the protocol has a specific reason.

The logic is indirect but real. Mast cells participate in wound biology, vascular changes, fibroblast communication, and inflammation timing. GHK-Cu literature overlaps with extracellular-matrix remodelling, collagen and elastin context, glycosaminoglycans, antioxidant response, and wound-repair signalling (PMC6073405; PMID: 18644225). If a GHK-Cu model changes the tissue environment, mast-cell behaviour may change secondarily.

That does not make GHK-Cu a mast-cell compound by default. A collagen marker does not prove mast-cell regulation. Faster closure does not prove reduced degranulation. Lower cytokines do not identify whether mast cells, keratinocytes, macrophages, fibroblasts, or endothelial cells carried the signal. A serious design would pair matrix endpoints with mast-cell endpoints: collagen I/III, MMP/TIMP balance, fibroblast markers, wound-edge histology, tryptase, histamine, cytokines, vascular markers, barrier integrity, and peptide recovery.

Copper context deserves extra controls. The material should be identified as GHK-Cu rather than a vague copper peptide. pH, chelators, serum proteins, oxidation, residual copper salts, storage, and vehicle compatibility can alter both matrix and immune readouts. A blue colour is not a COA.

Melanocortin and UV context: upstream stress is not a mast-cell endpoint#

Melanotan-1 can appear in mast-cell-adjacent skin research when UV exposure, melanocortin biology, pigmentation, photodamage, or MC1R-associated signalling is part of the experimental context. UV stress can affect barrier function, keratinocyte danger signals, oxidative stress, cytokines, vascular reactivity, and mast-cell state. That makes it an upstream context, not a direct mast-cell claim.

A UV-stress protocol might ask whether a melanocortin reference changes photodamage markers and whether mast-cell activation follows. But the claim should remain layered: UV-induced DNA damage, oxidative stress, pigmentation markers, barrier disruption, inflammatory cytokines, mast-cell markers, and vascular response are separate endpoints. Reduced UV injury is not the same claim as mast-cell stabilisation.

Northern Compound's pigmentation and melanogenesis guide and photoaging peptide guide cover that lane in more detail. In a mast-cell article, Melanotan-1 is a reminder to separate upstream stress biology from the mast-cell event being measured.

What to measure before making a mast-cell claim#

Degranulation markers#

Beta-hexosaminidase release is a common mast-cell degranulation assay, but it should not stand alone. Histamine, tryptase, chymase, granule imaging, calcium flux, and time-course sampling can help distinguish acute release from later inflammatory signalling. Controls should include a positive activator, vehicle, unstimulated baseline, viability, and assay-interference checks.

Histamine is useful, but incomplete#

Histamine is the familiar mediator, but mast-cell biology is broader than histamine. A histamine decrease may be meaningful in a histamine-driven model and irrelevant in a non-histaminergic itch model. It may also reflect depleted granules, assay interference, cytotoxicity, timing, or receptor-level effects outside the mast cell. A histamine claim should say exactly what changed and under what trigger.

Tryptase, chymase, and protease context#

Tryptase and chymase can support mast-cell activation and tissue-remodelling questions. They can also influence barrier proteins, protease-activated receptors, nerves, vessels, and matrix. If a peptide changes protease activity, the model should check whether that is direct enzyme interaction, altered release, altered cell number, or tissue degradation. Protease endpoints are powerful but easy to overread.

Cytokines and chemokines#

IL-1 beta, IL-6, IL-8, TNF-alpha, GM-CSF, CCL2, and related markers can describe inflammatory tone. They do not prove degranulation. They may originate from mast cells, keratinocytes, fibroblasts, macrophages, endothelial cells, or mixed tissue. Co-culture and tissue models should use cell-specific markers or spatial methods where possible.

Neurogenic and vascular endpoints#

Mast cells communicate with sensory nerves and vessels. Substance P, CGRP, TRPV1, TRPA1, nerve-fibre density, vascular flare, oedema, perfusion, and endothelial permeability can all matter depending on the model. If the claim involves itch or redness, a mast-cell marker alone is insufficient. Add nerve, vascular, barrier, and behaviour controls.

Barrier and keratinocyte controls#

Barrier damage can trigger mast-cell activation, and mast-cell mediators can worsen barrier leak. TEWL, permeability tracers, filaggrin, loricrin, involucrin, claudin-1, occludin, keratinocyte viability, and histology help locate the direction of effect. Without barrier controls, a mast-cell result may be downstream of simple irritation.

Model selection: what each system can prove#

Isolated mast-cell lines or primary mast cells are useful for narrow degranulation, mediator-release, calcium, receptor, and cytotoxicity questions. They cannot prove skin-level itch, redness, barrier function, microbial defence, or repair.

Keratinocyte-mast-cell co-cultures add epithelial context and can test crosstalk. They still simplify nerves, vessels, fibroblasts, microbiome signals, and barrier architecture. They need careful media and serum controls because immune peptides can bind proteins or behave differently under salt and serum conditions.

Reconstructed epidermis, full-thickness skin equivalents, or ex vivo skin can support barrier and tissue-architecture questions. They are stronger for topical exposure logic, histology, permeability, and multicellular interpretation. They still require tissue maturity, donor variability, humidity, vehicle, and peptide-recovery controls.

Animal models can capture neurogenic inflammation, scratching-like behaviour, vascular flare, wound timing, and systemic immune context. They also introduce species differences in mast-cell distribution, skin thickness, hair density, microbiome, stress response, and wound contraction. Animal results should remain model results, not human-use claims.

Human clinical or cosmetic literature, where relevant, is closest to visible skin outcomes but sits outside RUO purchasing guidance. Northern Compound can discuss such literature cautiously as context; it does not turn supplier materials into treatments or personal-use products.

Canadian RUO sourcing checklist for mast-cell-sensitive studies#

Mast-cell endpoints are vulnerable to artefacts. Endotoxin, microbial contamination, wrong salt form, residual solvent, oxidation, pH shift, freeze-thaw damage, inaccurate fill, adsorptive loss, and vehicle irritation can all move histamine, tryptase, cytokines, viability, and barrier readouts.

For LL-37, KPV, GHK-Cu, Melanotan-1, or Thymosin Alpha-1, Canadian readers should inspect:

1. lot-specific HPLC purity rather than a generic sample certificate;
2. mass or identity confirmation matching the named material;
3. exact peptide identity, sequence, complex form, salt form, and fill amount;
4. batch number, test date, re-test or manufacturing date, and storage guidance;
5. endotoxin and microbial-contamination awareness when immune-cell or cytokine endpoints are central;
6. solvent, buffer, pH, salt, serum, chelator, and vehicle compatibility;
7. peptide recovery from the actual assay matrix where binding or degradation is plausible;
8. light, heat, moisture, adsorption, and freeze-thaw stability considerations;
9. clear research-use-only labelling and no allergy, itch, redness, dermatitis, infection, wound-care, cosmetic-performance, dosing, or personal-use promises.

A product link is not a recommendation to use a compound. It is a route to inspect current supplier documentation while preserving attribution and avoiding raw store URLs. The study question, model design, and lot documentation remain the decision points.

How mast-cell peptide claims go wrong#

The first error is treating "mast-cell stabilisation" as a conclusion without direct degranulation data. Lower IL-6 is not mast-cell stabilisation. Less redness is not mast-cell stabilisation. Better barrier markers are not mast-cell stabilisation. The claim needs mast-cell-specific endpoints.

The second error is treating lower degranulation as automatically favourable. Degranulation can be excessive or harmful in some models, but mast cells also participate in defence, repair, and tissue communication. Suppressing mediator release in a sterile irritant assay is not the same as improving host defence in a microbial challenge.

The third error is ignoring cell death. A compound that injures mast cells may reduce mediator release because the cells are dying, depleted, or unable to signal. Viability, morphology, LDH release, ATP assays, and cell counts are not optional.

The fourth error is borrowing clinical language. Allergy, urticaria, dermatitis, rosacea, acne, infection, wounds, and itch are clinical or disease contexts. A cell or animal model can inform mechanisms, but it does not justify treatment claims for RUO materials.

The fifth error is ignoring barrier and nerve context. Mast cells rarely act alone in skin. Barrier disruption, keratinocyte alarmins, sensory-neuron neuropeptides, vascular response, microbial signals, and scratching damage can all create the mediator pattern. A strong study measures the surrounding system.

A practical evidence workflow for Canadian readers#

Start with a falsifiable claim. "KPV calms mast cells" is too broad. "In a keratinocyte-mast-cell co-culture challenged with substance P, a verified KPV lot changed beta-hexosaminidase release, histamine, IL-8, mast-cell viability, and keratinocyte viability relative to matched vehicle" is researchable. It names material, model, trigger, endpoints, comparator, and interpretation boundary.

Next, separate the mast-cell question from the supplier question. The mast-cell question asks whether the endpoint panel can actually support the claim. The supplier question asks whether the current lot can be trusted: identity, purity, fill, storage, endotoxin awareness, and RUO labelling. Both need to be strong. A perfect endpoint panel is weak if the vial is undocumented. A perfect COA does not prove biological effect.

Then check timing. Degranulation can happen within minutes. Cytokines can change over hours. Barrier disruption and tissue remodelling can unfold over days. Wound and UV models add still longer phases. A single time point can make a peptide look suppressive, activating, or irrelevant depending on when the sample was collected.

Finally, let the weakest layer limit the conclusion. If histamine falls but viability also falls, the result is uninterpretable until toxicity is resolved. If mast-cell markers change but barrier markers are absent, do not claim barrier repair. If redness improves but neurogenic markers are absent, do not claim a nerve mechanism. If a model is animal-based, do not convert it into human skin guidance.

Trigger taxonomy: the mast-cell question changes with the stimulus#

A mast-cell endpoint is only interpretable when the trigger is named. The same peptide can look useful, irrelevant, or problematic depending on whether the stimulus is IgE crosslinking, substance P, compound 48/80, microbial product, LL-37 exposure, UV-stressed keratinocyte media, irritant-challenged reconstructed epidermis, or wound-edge tissue.

IgE-dependent activation is the classic allergy-adjacent model. It can be useful for receptor biology, degranulation, calcium flux, and mediator release, but it should not be casually converted into skin-barrier or cosmetic claims. If the study uses IgE crosslinking, it should report Fc-epsilon receptor context, sensitisation conditions, antigen challenge, timing, and whether the peptide changes degranulation, viability, or receptor expression.

Neuropeptide-triggered activation belongs in neurogenic-inflammation research. Substance P, CGRP context, TRPV1/TRPA1 activation, heat, capsaicin, mechanical stress, and nerve-mast-cell co-culture can all move the system. This lane is relevant to itch-like and flushing-like models, but it requires nerve and behaviour controls. A mast-cell result without sensory-neuron context should not become a neurogenic claim.

Microbial and host-defence activation is a different lane. Bacterial products, fungal products, biofilms, antimicrobial peptides, TLR ligands, and cathelicidin processing can all influence mast cells and keratinocytes. LL-37 is most coherent here, but the design must include microbial burden, host-cell viability, salt and serum conditions, and barrier status if tissue is involved. Killing microbes in buffer is not the same as improving skin immune surveillance.

Barrier-disruption activation asks whether damaged epithelium is upstream of mast-cell signalling. Tape-stripping models, irritants, surfactants, dry-skin models, UV stress, and reconstructed-epidermis damage can all produce mediator changes. In this lane, TEWL, permeability, filaggrin, loricrin, claudin-1, keratinocyte alarmins, and histology are as important as histamine or tryptase. Without barrier endpoints, the mast-cell signal is floating without context.

Repair-phase activation is slower. Wound-edge models can include mast cells, macrophages, fibroblasts, endothelial cells, keratinocyte migration, matrix turnover, and microbial risk. GHK-Cu may be relevant here because repair and matrix biology are part of the hypothesis, but acute degranulation markers alone will not explain repair quality. A repair-phase study should include tissue closure, histology, collagen organisation, vascular markers, inflammatory timing, and peptide recovery.

The practical rule is to write the trigger into the claim sentence. "Peptide X reduced mast-cell activation" is weak. "Peptide X reduced substance-P-induced beta-hexosaminidase release in a mast-cell line without reducing viability" is usable. "Peptide X changed histamine release in an irritant-challenged reconstructed epidermis while TEWL and keratinocyte viability were measured" is stronger. Specificity protects the science.

Evidence hierarchy for mast-cell peptide claims#

Not every source deserves the same weight. A supplier page can tell readers what a lot claims to be. It cannot prove mast-cell biology. A cell assay can identify whether a material changes degranulation under controlled conditions. It cannot prove visible redness, itch, or barrier repair. A reconstructed-skin model can connect barrier and immune layers. It still lacks the full vascular, neural, endocrine, microbiome, and behavioural context of living skin.

For Northern Compound, the most useful posture is to combine evidence layers without merging them. Use authoritative reviews for the skin immune and mast-cell framework. Use compound-specific studies only for what they actually measured. Use supplier documentation to evaluate material identity and quality. Keep the final claim no broader than the weakest layer in the chain.

Documentation packet for a serious mast-cell study#

A credible mast-cell study should leave enough documentation for another lab to understand both the biology and the reagent. The minimum packet includes the hypothesis, model, trigger, peptide lot, storage history, vehicle, concentration range, exposure timing, sampling time, endpoint panel, viability method, assay-interference controls, statistical plan, and interpretation boundary.

For degranulation work, the packet should name the mast-cell source, culture conditions, sensitisation protocol if used, trigger, positive control, baseline release, total cellular content, normalisation method, and whether the peptide or vehicle interferes with fluorescence, absorbance, ELISA, or enzymatic detection. Mast-cell assays are vulnerable to false signals when a coloured compound, copper complex, residual solvent, pH shift, or detergent-like vehicle changes the readout.

For tissue work, the packet should describe tissue age, donor or animal details, anatomical site, humidity, temperature, topical or solution exposure, washing, barrier challenge, histology processing, and whether peptide recovery was measured from the tissue or medium. A mast-cell result in tissue is stronger when the study can show where the signal occurred: epidermis, dermis, vessel-adjacent region, follicle, wound edge, or inflammatory infiltrate.

For microbial work, the packet should name organism, strain, inoculum, growth phase, medium, salt concentration, serum or protein conditions, pH, biofilm status, exposure time, host-cell compatibility, microbial burden, and whether the peptide was recovered or degraded. This is especially important for LL-37, where salts, serum proteins, glycosaminoglycans, proteases, and microbial membranes can materially change activity.

For neurogenic work, the packet should include the stimulus, sensory-neuron context, neuropeptide markers, mast-cell markers, vascular or flare endpoint, behaviour endpoint if animal work is used, and locomotor or sedation controls. Itch-like behaviour is not just scratching counts. Scratching can be changed by stress, arousal, motor effects, pain sensitivity, sedation, or skin damage from prior scratching.

This documentation sounds procedural, but it is what separates useful research from a favourable marker graph. Mast-cell endpoints can move quickly, noisily, and for the wrong reasons. Without the packet, readers cannot tell whether a peptide changed mast-cell biology or whether the experiment measured contamination, toxicity, vehicle irritation, depletion, or timing artefact.

Product selection map: when each ProductLink is coherent#

Use LL-37 when the protocol names cathelicidin biology, antimicrobial challenge, microbial-host signalling, keratinocyte danger response, rosacea-like innate immunity, wound-edge host defence, or LL-37-specific mast-cell activation as the research question. Do not use it as a generic anti-redness or anti-itch reference.

Use KPV when the protocol names cytokine tone, NF-kB-adjacent signalling, epithelial inflammation, melanocortin-adjacent restraint, or cytokine interpretation in mast-cell-adjacent models. If the claim is acute degranulation, the study should directly measure histamine, tryptase, beta-hexosaminidase, or granule release rather than relying on cytokines.

Use GHK-Cu when mast-cell state is part of repair, fibroblast, extracellular-matrix, collagen, elastin, glycosaminoglycan, oxidative-stress, or wound-remodelling context. Do not use it as a mast-cell product unless mast-cell endpoints are present.

Use Melanotan-1 only when the upstream model involves UV stress, melanocortin signalling, pigmentation context, or photobiology. It is not a mast-cell compound by default.

Use Thymosin Alpha-1 only when the model explicitly includes broader immune coordination, antigen-presentation context, T-cell-adjacent biology, macrophage interaction, or host-defence timing. It should not be inserted into a skin mast-cell article as a generic immune-support reference.

That selection map keeps conversion useful rather than noisy. Product links should help readers inspect current RUO documentation for a compound that actually matches the study question. They should not turn every skin article into a list of loosely related products.

FAQ#

Bottom line#

Mast-cell skin peptide research is credible only when it is specific. Degranulation is not cytokine tone. Histamine is not itch. Vascular flare is not barrier repair. Lower inflammation is not automatically better. A serious article or protocol should say which mast-cell event is being studied before naming the compound.

For the current Northern Compound map, LL-37 is most coherent for cathelicidin, host-defence, microbial, keratinocyte-danger, and innate-immune models. KPV fits cytokine-restraint questions when degranulation and viability are measured separately. GHK-Cu fits repair and matrix-context models, not acute histamine claims by default. Melanotan-1 belongs only when UV or melanocortin biology is the upstream context.

The research-use-only standard is simple: define the trigger, measure the mast-cell event directly, control viability and barrier state, verify the lot, and keep the claim inside the data.